Literature DB >> 4074407

Pharmacological properties of the new potent diuretic torasemide in rats and dogs.

A Ghys, J Denef, J M de Suray, M Gerin, A Georges, J Delarge, J Willems.   

Abstract

Torasemide, a pyridine-3-sulfonylurea derivative, has potent diuretic activity in rats and dogs. In both species urinary volume and electrolyte excretion increased linearly with the logarithm of the dose, thus resembling the profile of a high ceiling diuretic. The minimum effective dose by oral route was 0.2 mg/kg in the rat and less that 0.1 mg/kg in the dog. Maximal effect was obtained with about 10 mg/kg. Experiments by oral and i.v. routes in the rat indicated that torasemide was equally potent by both oral and parenteral administration. In both rats and dogs, urinary excretions induced by torasemide were similar to those obtained with furosemide. However, for the same natriuretic effect, potassium losses with torasemide were significantly less than with furosemide. On a weight basis, torasemide was 9-40 times more potent than furosemide in the rat and about 10 times in the dog. After oral administration the diuretic effects of torasemide started within 20 min and lasted approximately 2 h in the rat and more than 8 h in the dog. The activity of torasemide was not decreased after a repeated daily oral dose of 10 mg/kg for 15 days in the rat. Torasemide at a daily oral dose of 5 mg/kg for 12 days effectively reduced the arterial blood pressure in desoxycortone induced hypertension in the rat. Besides the diuretic and antihypertensive effects no other significant pharmacological effects were observed with torasemide in the different in vitro and in vivo experiments. Torasemide was practically fully absorbed by the gastrointestinal tract, its bioavailability by oral route ranged from 80 to 100%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4074407

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  17 in total

Review 1.  A reappraisal of loop diuretic choice in heart failure patients.

Authors:  Jonathan Buggey; Robert J Mentz; Bertram Pitt; Eric L Eisenstein; Kevin J Anstrom; Eric J Velazquez; Christopher M O'Connor
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

2.  Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency.

Authors:  L Dodion; J L Willems
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment.

Authors:  D A Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

4.  Failure of indomethacin to impair the diuretic and natriuretic effects of the loop diuretic torasemide in healthy volunteers.

Authors:  E van Ganse; J Douchamps; F Deger; M Staroukine; A Verniory; A Herchuelz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Torasemide, a new potent diuretic. Double-blind comparison with furosemide.

Authors:  J Broekhuysen; F Deger; J Douchamps; H Ducarne; A Herchuelz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.

Authors:  A J Scheen; J C Vancrombreucq; J Delarge; A S Luyckx
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers.

Authors:  L Dodion; Y Ambroes; N Lameire
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  4-(3-Methyl-anilino)-N-[N-(1-methyl-ethyl)carbamo-yl]pyridinium-3-sulfon-amidate (torasemide) methanol 0.25-solvate 0.25-hydrate.

Authors:  Gianluca Bartolucci; Bruno Bruni; Silvia A Coran; Massimo Di Vaira
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-04-08

9.  Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis.

Authors:  H Knauf; E Mutschler; H Velazquez; G Giebisch
Journal:  Eur J Clin Pharmacol       Date:  2009-02-20       Impact factor: 2.953

10.  A simplified HPLC method for quantification of torsemide from human plasma and its application to a bioequivalence study.

Authors:  I J Khan; P Loya; M N Saraf
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.